CD40 and neoplasm: And recent studies demonstrate that it's possible to engineer a tumor-targeted CD40 molecule by conjugating a CD40 agonist mAb chemically with a tumor-homing peptide could potentially maximize antitumor potency while limiting systemic toxicity in clinical studies (33, 34).